Abstract:Purpose: High grade pleomorphic xanthoastrocytomas (HGPXAs) are very rare and their management and prognostic outcomes remain unclear. To better understand the disease, we aimed to evaluate the risk factors for progression-free survival (PFS) and overall survival (OS), and propose a treatment protocol based on cases from our institute and cases from the literature. Methods: The authors reviewed the clinical data of 26 patients with HGPXAs who underwent surgical treatment in Department of Neurosurgery of Beijing Tiantan Hospital between August 2014 and September 2021. We also searched the PubMed database using the keywords "anaplastic" combined with "pleomorphic xanthoastrocytoma(s)" between January 1997 and October 2022. Risk factors for PFS and OS were evaluated in the pooled cases. Results: The authors' cohort included 11 males and 15 females with a mean age of 36.7 ± 20.3 years (range: 5.5-71 years). Gross-total resection (GTR) and non-GTR were achieved in 17 (65.4%) and 9 (34.6%) patients, respectively. Radiotherapy and chemotherapy were administered to 22 and 20 patients, respectively. After a mean follow-up of 20.5 ± 21.2 months (range: 0.5-78.1 months), 7 patients suffered tumor recurrence and 6 patients died with a mean OS time of 19.4 ± 10.8 months (range: 8-36 months). In the literature between January 1997 and October 2022, 56 cases of HGPXAs were identified in 29 males and 27 females with a mean age of 29.6 ± 19.6 years (range; 4-74 years). Among them, 24 (44.4%) patients achieved GTR. Radiotherapy and chemotherapy was administered to 31 (62%) patients and 23 (46%) patients, respectively. After a median follow-up of 31.4 ± 35.3 months (range: 0.75-144 months), the mortality and recurrence rates were 32.5% (13/40) and 70% (28/40), respectively. Multivariate Cox regression model demonstrated that non-GTR (HR 0.380, 95% CI 0.174-0.831, p=0.015), age≥30 (HR 2.620, 95% CI 1.183-5.804, p=0.018), no RT (HR 0.334,95% CI 0.150-0.744, p=0.007) and no CT (HR 0.422, 95% CI 0.184-0.967, p=0.042) were negative prognostic factors for PFS. Non-GTR (HR 0.126, 95% CI 0.037-0.422, p=0.001), secondary HGPXAs (HR 7.567, 95% CI 2.221-25.781, p=0.001), age≥30 (HR 3.568, 95% CI 1.190-10.694, p=0.023) and no RT (HR 0.223,95% CI 0.073-0.681, p=0.008) were risk factors for OS. Conclusion:: High grade pleomorphic xanthoastrocytomas are very rare brain tumors. Children and younger adults have better clinical outcome than elderly patients. Secondary HGPXAs had worse OS than primary HGPXAs. Complete surgical excision plus RT and CT is recommended for this entity. The frequency of BRAF mutations in HGPXAs is 47.5% (19/40) in this study, however, we do not find the connections between BRAF mutations and clinical outcomes. Future studies with larger cohorts are necessary to verify our findings.

Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, and Epithelioid Glioblastoma: Case Series with Clinical Characteristics, Molecular Features and Progression Relationship

Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma

BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study

Clinicopathological, Morphological and Molecular study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma

Molecular Features of Pleomorphic Xanthoastrocytoma.

[Epithelioid Glioblastoma with BRAF V600E Mutation: a Clinicopathological and Molecular Study].

Clinical features and surgical outcomes of high grade pleomorphic xanthoastrocytomas: a single-center experience with a systematic review

Clinicopathologic study of pleomorphic xanthoastrocytoma and giant cell glioblastoma

Clinical Manifestations And Outcomes Of Typical Versus Atypical Pleomorphic Xanthoastrocytoma: A Single-Institution Experience

Analysis of Comparative Genomic Hybridization in Pleomorphic Xanthoastrocytoma

Exploring prognostic factors and treatment strategies for long-term survival in pleomorphic xanthoastrocytoma patients

Clinicopathological Features for Epithelioid Glioblastoma:A Newly Defined Tumor by the 2016 World Health Organization Classification of Tumors of the Central Nervous System

Primary Astrocytic Tumours and Paired Recurrences Have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss

Clinicopathological, immunohistochemical and therapeutic approaches on survival in patients with epithelioid glioblastoma: Institutional experience in the management of 58 patients

Path-34. It Never Rains But It Pours - Diagnosing Anaplastic Pleomorphic Xanthastrocytoma Twice In A Fortnight - Our Experience In A Resource Constrained Setting

Integrated genomic and transcriptomic analysis identified KRT18 mutation and MTAP loss as key genetic alterations related to the prognosis of astrocytoma and glioblastoma.

Surg-02. Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination Presenting With Cranial Neuropathy In An Adult Patient: Illustrative Case And Review Of The Literature

CLINICAL AND PATHOLOGICAL ANALYSIS OF 43 PATIENTS WITH EPITHELIOID GLIOBLASTOMA

The analysis of EGFR variants in Chinese adult glioblastoma patients.

Next Generation Sequencing and Molecular Imaging Identify EGFR Mutation and Amplification in a Glioblastoma Multiforme Patient Treated with an EGFR Inhibitor: a Case Report.

Integrated genomic and transcriptomic analysis identified <i>KRT18</i> mutation and <i>MTAP</i> loss as key genetic alterations related to the prognosis of astrocytoma and glioblastoma.